

373,984  
09/378,654**WEST**

Generate Collection

**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: US 5620852 A

L7: Entry 1 of 1

File: USPT

Apr 15, 1997

US-PAT-NO: 5620852

DOCUMENT-IDENTIFIER: US 5620852 A

TITLE: Nucleic acid preparation methods

DATE-ISSUED: April 15, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lin; Lily	Berkeley	CA	N/A	N/A
Cimino; George	Richmond	CA	N/A	N/A
Zhu; Yu S.	Richmond	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.1, 536/22.1, 536/25.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

Generate Collection

Term	Documents
LIGASE\$	0
LIGASE.DWPI,EPAB,JPAB,USPT.	10188
LIGASEAND.DWPI,EPAB,JPAB,USPT.	1
LIGASECATALYZED.DWPI,EPAB,JPAB,USPT.	2
LIGASED.DWPI,EPAB,JPAB,USPT.	11
LIGASEL.DWPI,EPAB,JPAB,USPT.	2
LIGASELYSYL.DWPI,EPAB,JPAB,USPT.	1
LIGASEPARSONS.DWPI,EPAB,JPAB,USPT.	1
LIGASEREACTION.DWPI,EPAB,JPAB,USPT.	2
LIGASES.DWPI,EPAB,JPAB,USPT.	1138
(L6 AND LIGASE\$).USPT,JPAB,EPAB,DWPI.	1

There are more results than shown above. [Click here to view the entire set.](#)

Display

10

Documents, starting with Document:

1

**Display Format:**

**WEST****End of Result Set**

Generate Collection

L7: Entry 1 of 1

File: USPT

Apr 15, 1997

DOCUMENT-IDENTIFIER: US 5620852 A

TITLE: Nucleic acid preparation methods

**BSPR:**

Where purification of RNA is for the purpose of producing template for amplification, it is important to consider the source (i.e. bone marrow, spinal fluid, urine, feces, etc.) and potential polymerase inhibitors that are constituents in such sources. One class of constituents known to inhibit nucleic acid associated enzymes are the "hemes" which include hemin and hematin. Hemin has been reported to inhibit virion-associated reverse transcriptase (RTase) of murine leukemia virus (MuLV) (Tsutsui and Mueller, BBRC 149: 628-634, 1987), DNA ligase (Scher et al., Can. Res. 48: 6278-6284, 1988), cytoplasmic DNA polymerase (Byrnes et al., Biochem. 14, 796-799, 1975), Taq polymerase (PCR Technology, H. A. Erlich (ed.) Stockton Press (1989) p.33), and other enzymatic systems that utilize ATP as a cofactor such as the hemin-controlled protein kinase that affects protein synthesis (Hronis and Traugh, J. Biol. Chem. 261, 6234-6238, 1986), the ATP-dependent ubiquitin-dependent protease pathway (Hershko et al., PNAS USA 81, 1619-1623, 1984), and the ATP-dependent ubiquitin-independent protease pathway (Waxman et al., J. Biol. Chem. 260, 11994-12000, 1985).

**BSPR:**

Experiments with DNA ligase indicate that hemin at 4 .mu.M or less does not affect DNA ligase activity or DNA substrate integrity. Scher et al., Can. Res. 48, 6278-6284, 1988. Preincubations of DNA ligase with hemin led to half-maximal inhibition of DNA ligase at hemin concentrations of 25-100 .mu.M (depending on the source of the DNA ligase). NAD-dependent DNA ligase from E. coli was not inhibited by hemin at concentrations up to 150 .mu.M. The inhibition of T4 DNA ligase activity and DNA ligase from mouse erythroleukemia (MEL) cells was not reversible by dilution, dialysis, or sucrose gradient centrifugation of cell-free extracts. Incubation of DNA ligase from MEL cells with hemoglobin was not inhibitory.

**BSPR:**

Binding assays demonstrate that hemin prevents association and causes dissociation of the DNA-cytoplasmic DNA polymerase complex. Hemin at a concentration of 12 .mu.M or higher completely inhibits the formation of DNA-enzyme complex. Byrnes et al., Biochem. 14, 796-799, 1975. This report also shows that hemin inhibition of DNA synthesis is competitive with respect to template and noncompetitive with respect to substrate. Furthermore, inhibition could be reversed by either 1) addition of globin to the polymerase-containing reaction mixture prior to the addition of hemin to the reaction mixture, or 2) addition of globin to hemin followed by addition of this mixture to the polymerase-containing reaction mixture. Inhibition could not be reversed by the addition of globin after introduction of hemin to the polymerase-containing reaction mixture

**BSPR:**

Experiments with purified hematin and related compounds have shown that they are potent inhibitors of Taq polymerase. Taq polymerase is used in the amplification procedure described by K. B. Mullis et. al., U.S. Pat. Nos. 4,683,195 and 4,683,202. This amplification procedure is a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of

thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (i.e. denaturation, annealing and extension constitute one "cycle;" there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to by the inventors as the "Polymerase Chain Reaction" (hereinafter PCR). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified".

**BSPR:**

The invention is particularly useful where it is desired to amplify said nucleic acid recovered in step (d). In a preferred embodiment, amplification is performed on recovered ribonucleic acid by adding a thermostable DNA polymerase having endogenous reverse transcriptase activity to said recovered ribonucleic acid. The method is compatible with the use of deoxyribonucleoside triphosphate dUTP (preferably at approximately 400 mM).

**DEPR:**

Template specificity is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Q.beta. replicase, MDV-1 RNA is the specific template for the replicase. D. L. Kacian et. al., Proc. Nat. Acad. Sci USA 69:3038 (1972). Other nucleic acid will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters. M. Chamberlin et al., Nature 228:227 (1970). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides where there is a mismatch between the oligonucleotide substrate and the template at the ligation junction. D. Y. Wu and R. B. Wallace, Genomics 4:560 (1989). Finally, Taq polymerase, by virtue of its ability to function at high temperature, is found to display high specificity for the sequences bound and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences. PCR Technology, H. A. Erlich (ed.) (Stockton Press 1989).

**DEPR:**

The present invention offers a radical change from the cumbersome nucleic acid whole blood method of density centrifugation and provides a flexible approach to whole blood processing for nucleic acid amplification (see FIG. 1). Importantly, the method of whole blood processing of the present invention can be carried out with i) only microliter amounts of blood (e.g. fingerstick or heelstick), ii) stored blood (including dried blood), and iii) the same, single reaction vessel used for amplification (allowing for quantitative recovery of cellular nucleic acid, in contrast, to the low-yield density centrifugation method). Because of these features, the method of the present invention is also amenable to automation.

**DEPR:**

The step of lysing the whole blood for release of RNA for conversion to cDNA is artful. It is important to release the RNA under conditions where it is not degraded due to simultaneous release of nucleases. The protease K must degrade the nucleases faster than the nucleases degrade the RNA, or if not, there will be no "net RNA" left for transcription by RT. In this experiment, free RNA was added to whole blood, and then lysis was carried out. To minimize the RNA loss, RNasin is added (which is a potent RNAse inhibitor) during the protease K step. Salt (KCl) and DTT concentration are very important. For optimum results the following reactions conditions were found:

**DEPR:**

Once RNA was recovered, this was amplified (5-10 .mu.l of the resuspension) by a

coupled RT/PCR amplification reaction using a thermostable DNA polymerase having endogenous reverse transcriptase activity ("rTth RT/PCR Kit", Perkin Elmer Cetus, Norwalk, Conn.) and the products detected with ethidium bromide on agarose gels. The procedure for the coupled RT/PCR assay was as follows:

DEPR:

In this example, deoxyribonucleic acid was made from ribonucleic acid which was recovered according to one embodiment of the sample preparation method of the present invention. The method of the present invention was compared as in Example 25 (above) by preparing known HCV plasma samples in parallel with the commercially available IsoQuick protocol (Microprobe Corp., Bothel, Wash.). Once RNA was recovered, this was amplified (5-10 ul of the resuspension) by a coupled RT/PCR amplification reaction using a DNA polymerase with endogenous reverse transcriptase activity ("rTth RT/PCR Kit", Perkin Elmer Cetus, Norwalk, Conn.) and the products detected with ethidium bromide on agarose gels. The procedure for the coupled RT/PCR assay was as described in Example 25.

DETL:

H.sub.2 O 6.3 .mu.l 10XRT Rxn. Buffer (100 mM Tris-HCl (pH 8.3), 2.0 .mu.l 900 mM KCl 10 mM MnCl.sub.2 -0.85 mM final concentration 1.7 .mu.l dNTP: 2 mM each dATP, dCTP, dGTP, & dTTP (in 2.0 .mu.l H.sub.2 O, pH 7.0) RT "downstream" primer KY78 (1.5 .mu.M in H.sub.2 O) - 2.0 .mu.l 3 picomole/rxn. PCR "upstream" primer KY80 (1.5 .mu.M in H.sub.2 O) - 2.0 .mu.l 3 picomole/rxn. rTth DNA polymerase: 2.5 units/ul in 2.0 .mu.l 1X Enzyme storage buffer = 20 mM Tris-HCl (pH 7.5), 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.2% Tween (Pierce Surfactants), 50% glycerol (v/v) Template nucleic acid: less than 250 ng total in TE, 2.0 .mu.l 10 mM Tris 1 mM EDTA) Total Reaction volume 20.0 .mu.l

CLPR:

10. The method of claim 9 wherein said amplifying of said ribonucleic acid is performed by adding a thermostable DNA polymerase having endogenous reverse transcriptase activity to said recovered ribonucleic acid.

CLPR:

14. The method of claim 7 wherein said amplifying of said ribonucleic acid is performed by adding a thermostable DNA polymerase having endogenous reverse transcriptase activity to said recovered ribonucleic acid.

CLPR:

19. The method of claim 13 wherein said amplifying of said ribonucleic acid is performed by adding a thermostable DNA polymerase having endogenous reverse transcriptase activity to said recovered ribonucleic acid.

09373.124

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:ssspta1806jxt  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical  
Substances (PICCS) has been added to CHEMLIST  
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent  
Files  
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in  
Derwent World Patents Index files  
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available  
in Derwent Patent Files  
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to  
Derwent Subscriber Files WPIDS and WPIX  
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI  
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN  
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files  
NEWS 10 Dec 15 2001 STN Pricing  
NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and  
biotechnology  
NEWS 12 Dec 17 Corrosion Abstracts on STN  
NEWS 13 Dec 17 SYNTHLINE from Prous Science now available on STN  
NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 15 Jan 05 AIDSLINE is being removed from STN  
NEWS 16 Feb 06 Engineering Information Encompass files have new names  
NEWS 17 Feb 16 TOXLINE no longer being updated  
  
NEWS EXPRESS FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!  
(WINDOWS) NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 12:58:59 ON 14 MAR 2001

=> file medline biosis caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FILE 'MEDLINE' ENTERED AT 12:59:34 ON 14 MAR 2001

FILE 'BIOSIS' ENTERED AT 12:59:34 ON 14 MAR 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CAPLUS' ENTERED AT 12:59:34 ON 14 MAR 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (single reaction or single vessel or one vessel) (10a)DNA  
polymerase#(10a)RNA polymerase#(10a)reverse transcriptase#(10a)ligase

L1 0 (SINGLE REACTION OR SINGLE VESSEL OR ONE VESSEL) (10A) DNA  
POLYME  
RASE#(10A) RNA POLYMERASE#(10A) REVERSE TRANSCRIPTASE#(10A)  
LIGASE

=> (single reaction or single vessel or one vessel) (10a)DNA  
polymerase#(10a)RNA polymerase#(10a)reverse transcriptase#(10a)RNase

(SINGLE IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s (single reaction or single vessel or one vessel) (10a)DNA  
polymerase#(10a)RNA polymerase#(10a)reverse transcriptase#(10

MISSING OPERATOR 'SCRIPTASE#(10'  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s single reaction or single vessel or one vessel

L2 5858 SINGLE REACTION OR SINGLE VESSEL OR ONE VESSEL

=> s 12 and DNA polymerase# and RNA polymerase# and reverse transcriptase#  
and RNase#

L3 2 L2 AND DNA POLYMERASE# AND RNA POLYMERASE# AND REVERSE  
TRANSCRIP  
TASE# AND RNASE#

=> d 13 1-2 bib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:344534 CAPLUS  
DN 129:13211  
TI Method and kit for direct isothermal sequencing of nucleic acids  
IN Dunn, James M.; Digby, Thomas J.  
PA Visible Genetics Inc., Can.; Dunn, James M.; Digby, Thomas J.  
SO PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 9821361 A1 19980522 WO 1997-CA848 19971112  
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,

KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,  
 US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

AU 9749384 A1 19980603 AU 1997-49384 19971112  
 PRAI US 1996-31257 19961112  
 WO 1997-CA848 19971112

AB Direct detn. of the sequence of an RNA sample is performed under isothermal conditions. An RNA sample contg. a target nucleic acid is combined in a **single reaction** vessel with a reaction mixt. contg. two polynucleotide primers, a first primer that specifically hybridizes with a target sequence near the 3' end of an antisense copy of the target nucleic acid. At least one of the primers is labeled with a detectable label, and at least one of the first or second primers has an **RNA polymerase** transcription initiation signal at its 5' end, which signal does not specifically hybridize to the RNA target. The reaction mixt. also contains ribonucleotide triphosphates for RNA synthesis, deoxyribonucleotide triphosphates for DNA synthesis, at least one type of dideoxynucleotide triphosphate chain-terminator, and enzymes with the activity of **reverse transcriptase**, **RNAse H**, **RNA Polymerase** and a low discrimination **DNA Polymerase** such as Thermo Sequenase<sup>TM</sup>. The combined reactants are incubated under isothermal conditions for a length of time sufficient to generate chain-terminated reaction products, and the chain-terminated reaction products are then detected after electrophoretic sepn.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:458032 CAPLUS  
 DN 125:107035  
 TI Terminal repeat amplification method for nucleic acids  
 IN Sooknanan, Roy; Malek, Lawrence  
 PA Akzo Nobel N.V., Neth.  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617079	A1	19960606	WO 1995-EP4694	19951128
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5665545	A	19970909	US 1994-345505	19941128
	CA 2205563	AA	19960606	CA 1995-2205563	19951128
	AU 9641767	A1	19960619	AU 1996-41767	19951128
	AU 711589	B2	19991014		
	EP 796343	A1	19970924	EP 1995-940256	19951128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	JP 10510161	T2	19981006	JP 1995-518184	19951128
	FI 9702238	A	19970527	FI 1997-2238	19970527
PRAI	US 1994-345505		19941128		
	WO 1995-EP4694		19951128		
AB	This invention relates to a process for amplifying a specific nucleic acid sequence or its complement at a relatively const. temp. and without serial addn. of reagents. The process provides in a <b>single</b>				



reaction medium an **RNA polymerase**, **DNA polymerase**, a **RNase** that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA, and ribonucleoside and deoxyribonucleoside triphosphates. The process then provides an RNA first template in the reaction medium. The RNA first template comprises a sequence complementary to a specific nucleic acid sequence, minus-sense sequences for a promoter and initiation site that are recognized by the **RNA polymerase**, and a 5'-terminal sequence that is complementary to at least the minus-sense sequence of the initiation site. Thus, the RNA first template has in inverted repeat sequence which could fold into a 5'-terminal stem-loop structure. The **DNA polymerase** uses the RNA first template to synthesize a DNA second template that together comprise an RNA-DNA hybrid. The DNA second template has plus-sense sequences of the promoter and the initiation site, and a 3'-terminal priming sequence that is complementary to the plus-sense sequence of the initiation site. The **RNase** then hydrolyzes an RNA which comprises the RNA-DNA hybrid, allowing the 3'-terminal priming sequence to hybridize to the plus-sense sequence of the initiation site in the DNA second template. The **DNA polymerase** then uses the DNA second template to synthesize the promoter by extending the 3'-terminal priming sequence of the DNA second template. The resulting partially double-stranded DNA has a promoter oriented toward the apex of a stem-loop structure. The **RNA polymerase** then recognizes the promoter and transcribes the DNA second template, thereby providing copies of the RNA first template. The process thereafter maintains the reaction conditions for a time sufficient to achieve a desired amplification of the specific nucleic acid sequence or its complement. This invention includes a kit contg. the reagents of this invention.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:458032 CAPLUS  
 DN 125:107035  
 TI Terminal repeat amplification method for nucleic acids  
 IN Sooknanan, Roy; Malek, Lawrence  
 PA Akzo Nobel N.V., Neth.  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617079	A1	19960606	WO 1995-EP4694	19951128
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5665545	A	19970909	US 1994-345505	19941128
	CA 2205563	AA	19960606	CA 1995-2205563	19951128
	AU 9641767	A1	19960619	AU 1996-41767	19951128
	AU 711589	B2	19991014		
	EP 796343	A1	19970924	EP 1995-940256	19951128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE JP 10510161 T2 19981006 JP 1995-518184 19951128  
 FI 9702238 A 19970527 FI 1997-2238 19970527

PRAI US 1994-345505 19941128  
 WO 1995-EP4694 19951128

AB This invention relates to a process for amplifying a specific nucleic acid

sequence or its complement at a relatively const. temp. and without serial

addn. of reagents. The process provides in a **single reaction** medium an **RNA polymerase**, **DNA polymerase**, a **RNase** that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA, and ribonucleoside and deoxyribonucleoside triphosphates. The process then provides an RNA first template in the reaction medium. The RNA first template comprises a sequence complementary to a specific nucleic acid sequence, minus-sense sequences for a promoter and initiation site that are recognized by the **RNA polymerase**, and a 5'-terminal sequence that is complementary to at least the minus-sense sequence of the initiation site. Thus, the RNA first template has in inverted repeat sequence which could fold into a 5'-terminal stem-loop structure. The **DNA polymerase** uses the RNA first template to synthesize a DNA second template that together comprise an RNA-DNA hybrid. The DNA second template has plus-sense sequences of the promoter and the initiation site, and a 3'-terminal priming sequence that is complementary to the plus-sense sequence of the initiation site. The **RNase** then hydrolyzes an RNA which comprises the RNA-DNA hybrid, allowing the 3'-terminal priming sequence to hybridize to the plus-sense sequence of the initiation site in the DNA second template. The **DNA polymerase** then uses the DNA second template to synthesize the promoter by extending the 3'-terminal priming sequence of the DNA second template. The resulting partially double-stranded DNA has a promoter oriented toward the apex of a stem-loop structure. The

**RNA polymerase** then recognizes the promoter and transcribes the DNA second template, thereby providing copies of the RNA first template. The process thereafter maintains the reaction conditions for a time sufficient to achieve a desired amplification of the specific nucleic acid sequence or its complement. This invention includes a kit contg. the reagents of this invention.

AB This invention relates to a process for amplifying a specific nucleic acid

sequence or its complement at a relatively const. temp. and without serial

addn. of reagents. The process provides in a **single reaction** medium an **RNA polymerase**, **DNA polymerase**, a **RNase** that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA, and ribonucleoside and deoxyribonucleoside triphosphates. The process then provides an RNA first template in the reaction medium. The RNA first template comprises a sequence complementary to a specific nucleic acid sequence, minus-sense sequences for a promoter and initiation site that are recognized by the **RNA polymerase**, and a 5'-terminal sequence that is complementary to at least the minus-sense sequence of the initiation site. Thus, the RNA first template has in inverted repeat sequence which could fold into a 5'-terminal stem-loop structure. The **DNA polymerase** uses the RNA first template to synthesize a DNA second template that together comprise an RNA-DNA hybrid. The DNA second template has plus-sense sequences of the promoter and the initiation site, and a 3'-terminal priming sequence that is complementary to the plus-sense sequence of the initiation site. The **RNase** then hydrolyzes an RNA which comprises the RNA-DNA hybrid, allowing the 3'-terminal priming sequence to hybridize to the plus-sense sequence of the initiation site in the DNA second template. The **DNA polymerase** then uses the DNA second template to synthesize the promoter by extending the 3'-terminal priming sequence of the DNA second template. The resulting partially double-stranded DNA has a promoter oriented toward the apex of a stem-loop structure. The **RNA polymerase** then recognizes the promoter and transcribes the DNA second template, thereby providing copies of the RNA first template. The process thereafter maintains the reaction conditions for a time sufficient to achieve a desired amplification of the specific nucleic acid sequence or its complement. This invention includes a kit contg. the reagents of this invention.

- IT Virus, animal  
(Moloney murine leukemia, **reverse transcriptase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, bacterial  
(SP6, **RNA polymerase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, bacterial  
(T3, **RNA polymerase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, bacterial  
(T7, **RNA polymerase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, animal  
(avian myeloblastosis, **reverse transcriptase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, bacterial  
(gh-1, **RNA polymerase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, bacterial  
(phi II, **RNA polymerase** for use in TRAM technique from; terminal repeat amplification method for nucleic acids)
- IT Virus, animal  
(retro-, **reverse transcriptase** for use in TRAM

technique from; terminal repeat amplification method for nucleic acids)

IT 9014-24-8, **RNA polymerase** 9015-85-4, DNA  
**ligase** 9050-76-4, **RNase H** 9068-38-6, **Reverse transcriptase**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(terminal repeat amplification method for nucleic acids)